Yuhui Yuan

Dr. Yuhui Yuan


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 September 2014 in Journal of Pineal Research
Verified
Journal Article
Closed access
PDF file
HJHaifeng Jin
Haifeng Jin
YWYueyue Wang
Yueyue Wang
LZLei Zhou
Lei Zhou
LLLu Liu
Lu Liu
PZPeng Zhang
Peng Zhang
YYYuhui Yuan
Yuhui Yuan

1 October 2016 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
HJHaifeng Jin
Haifeng Jin
MLMingcheng Liu
Mingcheng Liu
XZXin Zhang
Xin Zhang
JPJinjin Pan
Jinjin Pan
JHJinzhen Han
Jinzhen Han
YYYuhui Yuan
Yuhui Yuan

7 March 2024 in Oncogene
Verified
Journal Article
Closed access
PDF file
KCKe Cheng
Ke Cheng
JPJinjin Pan
Jinjin Pan
QLQinlong Liu
Qinlong Liu
YJYuke Ji
Yuke Ji
LLLiang Liu
Liang Liu
YYYuhui Yuan
Yuhui Yuan

9 October 2022 in The Journal of Nutritional Biochemistry
Verified
Journal Article
Closed access
JPJinjin Pan
Jinjin Pan
RWRui Wang
Rui Wang
YPYandong Pei
Yandong Pei
DWDingyou Wang
Dingyou Wang
NWNa Wu
Na Wu
YYYuhui Yuan
Yuhui Yuan

11 June 2015 in Oncology Reports
Verified
Journal Article
Closed access
PDF file
SLSiwei Liu
Siwei Liu
LZLei Zhou
Lei Zhou
YZYongshun Zhao
Yongshun Zhao
YYYuhui Yuan
Yuhui Yuan
Glioblastoma multiforme (GBM), a tumor associated with poor prognosis, is known to be resistant to radiotherapy and alkylating agents such as temozolomide (TMZ). β-elemene, a monomer found in Chinese traditional herbs extracted from Curcuma wenyujin, is currently being used as an antitumor drug for different types of tumors including GBM. In the present study, we investigated the roles of β-elemene in the radiosensitivity and chemosensitivity of GBM cells. Human GBM cell lines U87-MG, T98G, U251, LN229 and rat C6 cells were treated with β-elemene combined with radiation or TMZ. We used MTT and colony forming assays to evaluate the proliferation and survival of the cells, and the comet assay to observe DNA damage. Expression of proteins was analyzed by immunoblotting. In the present study, we found that β-elemene inhibited the proliferation and survival of different GBM cell lines when combined with radiotherapy or TMZ via inhibition of DNA damage repair. Treatment of GBM cells with β-elemene decreased the phosphorylation of ataxia telangiectasia mutated (ATM), AKT and ERK following radiotherapy or chemotherapy. These results revealed that β-elemene could significantly increase the radiosensitivity and chemosensitivity of GBM. β-elemene may be used as a potential drug in combination with the radiotherapy and chemotherapy of GBM.

14 October 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
MGMiaomiao Gong
Miaomiao Gong
XWXun Wang
Xun Wang
LMLin Mu
Lin Mu
YWYueyue Wang
Yueyue Wang
JPJinjin Pan
Jinjin Pan
YYYuhui Yuan
Yuhui Yuan
Glioblastoma (GBM) recurrence is attributed to the presence of therapy‐resistant glioblastoma stem cells. Steroid receptor coactivator‐1 (SRC‐1) acts as an oncogenic regulator in many human tumors. The relationship between SRC‐1 and GBM has not yet been studied. Herein, we investigate the role of SRC‐1 in GBM. In this study, we found that SRC‐1 expression is positively correlated with grades of glioma and inversely correlated with glioma patient’s prognosis. Steroid receptor coactivator‐1 promotes the proliferation, migration, and tumor growth of GBM cells. Notably, SRC‐1 knockdown suppresses the stemness of GBM cells. Mechanistically, long noncoding RNA X‐inactive specific transcript (XIST) is regulated by SRC‐1 at the posttranscriptional level and mediates the function of SRC‐1 in promoting stemness‐like properties of GBM. Steroid receptor coactivator‐1 can promote the expression of Kruppel‐like factor 4 (KLF4) through the XIST/microRNA (miR)‐152 axis. Additionally, arenobufagin and bufalin, SRC small molecule inhibitors, can reduce the proliferation and stemness of GBM cells. This study reveals SRC‐1 promotes the stemness of GBM by activating the long noncoding RNA XIST/miR‐152/KLF4 pathway and provides novel markers for diagnosis and therapy of GBM.